ArticleBMC cancer2024

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

J C Janssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.